The PLS-NAFLD signature was found to be modifiable by interventions such as bariatric surgery, lipophilic statin, and IDO1 inhibitor, suggesting its potential utility in drug discovery and as a surrogate endpoint in clinical trials for HCC chemoprevention in NAFLD [93]. Here, IDO1 is linked to metabolic dysfunction-associated steatotic liver disease.